IceCure Medical (NASDAQ:ICCM) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $2.50 price target on the stock.

Separately, Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a research report on Friday, November 1st.

IceCure Medical Trading Up 5.8 %

Shares of NASDAQ ICCM opened at $0.83 on Wednesday. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.57. The company has a market cap of $37.96 million, a price-to-earnings ratio of -2.77 and a beta of 0.48. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. The stock’s 50 day simple moving average is $0.64 and its 200 day simple moving average is $0.73.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.